1 |
Molina R, Filella X, Auge JM, et al (2003). Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol, 24, 209-18.
DOI
ScienceOn
|
2 |
Gaarenstroom KN, Bonfrer JM, Kenter GG, et al (1995). Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer, 76, 807-13.
DOI
|
3 |
Chen XJ, Li N, Huang YD, et al (2014). Factors for postoperative gallstone occurrence in patients with gastric cancer: a metaanalysis. Asian Pac J Cancer Prev, 15, 877-81.
과학기술학회마을
DOI
ScienceOn
|
4 |
Choi AR, Park JC, Kim J, et al (2013). High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol, 19, 5302-8.
DOI
ScienceOn
|
5 |
Duraker N, Celik AN (2001). The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol, 76, 266-71.
DOI
ScienceOn
|
6 |
Gartner U, Scheulen ME, Conradt C, et al (1998). Value of tumor-associated antigens CA 72-4 vs CEA and CA 19-9 in the follow-up after stomach cancer. Dtsch Med Wochenschr, 123, 69-73.
DOI
ScienceOn
|
7 |
Ikeguchi M, Katano K, Saitou H, et al (1997). Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterology, 44, 866-71.
|
8 |
Japanese Gastric Cancer Association (2011). Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer, 14, 101-12.
DOI
ScienceOn
|
9 |
Kodama I, Koufuji K, Kawabata S, et al (1995). The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg, 80, 45-8.
|
10 |
Kodera Y, Yamamura Y, Torii A, et al (1996). The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol, 91, 49-53.
|
11 |
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA: A Cancer J Clin, 63, 11-30.
DOI
ScienceOn
|
12 |
Zhang HQ, Wang RB, Yan HJ, et al (2012). Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev, 13, 199-203.
과학기술학회마을
DOI
ScienceOn
|
13 |
Zhu SJ, Zhang Y, Yu YH, et al (2013). FDG PET-CT in non-small cell lung cancer: relationship between primary tumor fdg uptake and extensional or metastatic potential. Asian Pac J Cancer Prev, 14, 2925-29.
과학기술학회마을
DOI
ScienceOn
|
14 |
Sisik A, Kaya M, Bas G, Basak F, Alimoglu O (2013). CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev, 14, 4289-94.
과학기술학회마을
DOI
ScienceOn
|
15 |
Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K (2004). Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer, 91, 873-8.
DOI
|
16 |
Qin H, Qu LL, Liu H, Wang SS, Gao HJ (2013). Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4205-8.
과학기술학회마을
DOI
ScienceOn
|
17 |
Ubukata H, Katano M, Motohashi G, et al (2003). Evaluation of CA72-4 as a tumor marker in patients with gastric cancer. Gan To Kagaku Ryoho, 30, 1821-4.
|
18 |
Ucar E, Semerci E, Ustun H, et al (2008). Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther, 25, 1075-84.
DOI
ScienceOn
|
19 |
Waldum HL, Aase S, Kvetnoi I, et al (1998). Neuroendocrine differentiation in human gastric carcinoma. Cancer, 83, 435-44.
DOI
|
20 |
Wieskopf B, Demangeat C, Purohit A, et al (1995). Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest, 108, 163-9.
DOI
ScienceOn
|
21 |
Koga T, Kano T, Souda K, Oka N, Inokuchi K(1987). The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg, 17, 342-7.
DOI
ScienceOn
|
22 |
Yoshioka T, Yamaguchi K, Kubota K, et al (2003). Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med, 44, 690-9.
|
23 |
Zeltzer PM, Marangos PJ, Evans AE, Schneider SL (1986). Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer, 57, 1230-4.
DOI
|
24 |
Koenig A, Wojcieszyn J, Weeks BR, Modiano JF (2001). Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma. Vet Pathol, 38, 427-35.
DOI
ScienceOn
|
25 |
Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981). Specific antigen in serum of patients with colon carcinoma. Science, 212, 53-5.
DOI
|
26 |
Lee JH (2013). Clinical usefulness of serum CYFRA 21-1 in patients with colorectal cancer. Nucl Med Mol Imaging, 47, 181-7.
DOI
ScienceOn
|
27 |
Liu X, Cai H, Wang Y (2012). Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol, 10, 1-9.
DOI
|
28 |
Moertel CG, O'Fallon JR, Go VL, O'Connell MJ, Thynne GS (1986). The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer, 58, 603-10.
DOI
|
29 |
Mattar R, Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA (2002). Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo, 57, 89-92.
DOI
|
30 |
Lee IK, Kim DH, Gorden DL, et al (2009). Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer. Ann Surg Oncol, 16, 861-70.
DOI
ScienceOn
|
31 |
Jung KW, Won YJ, Kong HJ, et al (2013). Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res and Treat, 45,1-14.
DOI
ScienceOn
|